ICM
TBPH icon

Irenic Capital Management’s Theravance Biopharma TBPH Stock Holding History

Irenic Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.9M Hold
2,760,948
– – 2.25% 12
2026
Q1 		$44.8M Hold
2,760,948
– – 2.92% 8
2025
Q4 		$51.7M Hold
2,760,948
– – 3.47% 4
2025
Q3 		$40.3M Hold
2,760,948
– – 4.22% 6
2025
Q2 		$30.5M Hold
2,760,948
– – 4.49% 7
2025
Q1 		$24.7M Hold
2,760,948
– – 3.74% 9
2024
Q4 		$26M Hold
2,760,948
– – 2.79% 14
2024
Q3 		$22.3M Hold
2,760,948
– – 1.95% 13
2024
Q2 		$23.4M Hold
2,760,948
– – 2.86% 9
2024
Q1 		$24.8M Hold
2,760,948
– – 5.05% 7
2023
Q4 		$31M Hold
2,760,948
– – 6.15% 5
2023
Q3 		$23.8M Hold
2,760,948
– – 6.76% 3
2023
Q2 		$28.6M Sell
2,760,948
-3,100
-0.1% -$34.2K 8.53% 4
2023
Q1 		$30M Buy
2,764,048
+1,063,111
+63% +$11.2M 10.35% 4
2022
Q4 		$19.1M Buy
+1,700,937
New +$17.9M 9.15% 3

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Irenic Capital Management's TBPH Position: Q2 2026 in Review

Irenic Capital Management held its Theravance Biopharma (TBPH) position steady in Q2 2026 at 2,760,948 shares worth $46.9M. The position accounts for 2.25% of the portfolio, ranked #12.

Irenic Capital Management first reported a position in TBPH in Q4 2022 and has held it in 15 quarters since. The position peaked at $51.7M in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Irenic Capital Management held 2,760,948 shares of Theravance Biopharma worth $46.9M as of Q2 2026.
  • Irenic Capital Management left its Theravance Biopharma share count unchanged in Q2 2026.
  • Theravance Biopharma made up 2.25% of Irenic Capital Management's portfolio in Q2 2026, its #12 holding.
  • Irenic Capital Management first reported a position in Theravance Biopharma in Q4 2022 and has held it in 15 quarters since.
  • Irenic Capital Management's Theravance Biopharma position peaked at $51.7M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Irenic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.